Full-Time
Atomistic drug-discovery simulation platform
$164.6k - $259k/yr
San Francisco, CA, USA + 1 more
More locations: New York, NY, USA
Hybrid
Achira develops atomistic foundation simulation models for drug discovery, combining geometric deep learning, physics, quantum chemistry, and statistical mechanics to create advanced potentials and generative models. These models produce large synthetic datasets free from experimental artifacts, enabling true inverse design where researchers optimize compounds from desired properties. Achira serves pharmaceutical and biotech clients through partnerships, licensing, and collaborations, differentiating itself by integrating physics-based simulations with data-driven learning to mitigate data scarcity and high costs. The company's goal is to accelerate and make drug discovery more reliable by enabling inverse design that reduces time and expenses in identifying promising compounds.
Company Size
11-50
Company Stage
Seed
Total Funding
$33M
Headquarters
New York City, New York
Founded
2024
Help us improve and share your feedback! Did you find this helpful?
People at Achira who can refer or advise you
Remote Work Options
Hybrid Work Options
Flexible Work Hours
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
PTO/vacation
Paid Vacation
Paid Holidays
Unlimited Paid Time Off
401(k) Retirement Plan
Stock Options
Company Equity
Wellness Program
Mental Health Support
Gym Membership
Conference Attendance Budget
Professional Development Budget
Phone/Internet Stipend
Home Office Stipend
Family Planning Benefits
Fertility Treatment Support
Professional Development Budget
Confluence
Greek startup Achira AI has secured $33 million in funding from top investors, including Dimension, Nvidia, Amplify, and Compound. Achira aims to revolutionize AI-enabled drug development by integrating geometric deep learning, physics, quantum chemistry, and statistical mechanics to create advanced simulation models. This approach seeks to overcome limitations in current biomolecular simulations and machine learning models, accelerating the discovery of new molecules and treatments.
As he was testing new antivirals to halt a future pandemic, John Chodera encountered an unlikely set of new problems that ultimately helped lead to his new job. The computational ...